Pain Therapeutics Inc. (PTIE)

1.34
0.10 8.06
NASDAQ : Health Technology
Prev Close 1.24
Open 1.25
Day Low/High 1.24 / 1.34
52 Wk Low/High 0.76 / 8.76
Volume 454.46K
Avg Volume 278.10K
Exchange NASDAQ
Shares Outstanding 17.22M
Market Cap 19.97M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pain Therapeutics Loses Half Its Value After Revealing Dispute With FDA

Pain Therapeutics Loses Half Its Value After Revealing Dispute With FDA

This small drug company loses half of its value. See why.

Pain Therapeutics Reports Positive Regulatory Meeting For REMOXY™

Pain Therapeutics Reports Positive Regulatory Meeting For REMOXY™

Resubmission of the REMOXY NDA On-Track for Q1 2018

Pain Therapeutics Announces New Publication On Alzheimer's Disease

Pain Therapeutics Announces New Publication On Alzheimer's Disease

Peer-reviewed Publication Supports On-Going Clinical Development of PTI-125

Pain Therapeutics Announces Upcoming Meeting With FDA

Pain Therapeutics Announces Upcoming Meeting With FDA

Pre-NDA Meeting, November 14th for REMOXY™ ER

Pain Therapeutics Announces Successful Phase I Clinical Study For PTI-125

Pain Therapeutics Announces Successful Phase I Clinical Study For PTI-125

PTI-125 Is Well-Tolerated in First-in-human Clinical Study

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.

National Institute On Drug Abuse Awards Pain Therapeutics $2.2 Million Grant

National Institute On Drug Abuse Awards Pain Therapeutics $2.2 Million Grant

Provides Funding for FENROCK™, an Abuse-deterrent Pain Patch

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Clinical Study Initiation Is Expected Shortly, with Funding by NIH

NIH Awards $1.7 Million Research Grant To Pain Therapeutics To Study Alzheimer's Disease

NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate

Pain Therapeutics Announces Research Publication On Alzheimer's Disease

PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease

Pain Therapeutics Announces Reverse Stock Split

Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017

Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER

- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -

Pain Therapeutics To Discuss REMOXY® ER With FDA

Pain Therapeutics To Discuss REMOXY® ER With FDA

FDA Meeting Set for February 13, 2017

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Putting 2 Biotechs Under the Microscope

These low-dollar biotech stocks are making big moves Monday -- in opposite directions.

Complete Response Letter For REMOXY®

Complete Response Letter For REMOXY®

Company Will Host Conference Call Monday, September 26th at 9:00am EDT